Literature DB >> 3569136

Receptor-mediated interrelationships between progesterone and estradiol action on the anterior pituitary-hypothalamic axis of the ovariectomized immature rat.

J J Calderon, T G Muldoon, V B Mahesh.   

Abstract

The ovariectomized immature rat was used as a model for analysis of action of progesterone as a modulator of receptor-mediated functional responsiveness in the anterior pituitary and hypothalamus. In response to estrogen exposure, cytosolic progesterone receptors appear rapidly, rise in concentration to a peak at 12 h, then fall to a plateau level well above control, which is maintained for at least an additional 20 h. Progesterone administration at the peak 12-h interval induces maximal nuclear accumulation of its own receptor within 1-2 h, with apparent extensive processing occurring thereafter. To this point, no differences were seen between anterior pituitary and hypothalamic responses. If animals were administered progesterone (0.8 mg/kg BW) at the 12-h peak interval, subsequent nuclear accumulation of anterior pituitary estrogen receptor by an injection of estradiol was suppressed if, and only if, the interval between progesterone and estradiol injection did not exceed 2 h; at no time interval did progesterone have an effect in the hypothalamus. In both tissues, estradiol readministration at 12 h after an initial injection stimulates a second wave of progesterone receptor activity, again peaking 12 h later. A single injection of progesterone 1 h before the second estradiol administration blocks the second peak of progesterone receptor in the anterior pituitary, but not in the hypothalamus. If the interval between the progesterone and second estradiol injections is extended to 4 h, the second progesterone receptor peak appears as though no progesterone had been introduced. The results indicate a critical temporal reliance of the inhibitory effects of progesterone on estrogen receptor activity and estrogen function in a well defined animal model. The effect is progesterone receptor-mediated and is manifested in the anterior pituitary, but not in the hypothalamus, even though the kinetics of estrogen-induced progesterone receptor activity are indistinguishable between the two tissues.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3569136     DOI: 10.1210/endo-120-6-2428

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Progesterone together with estrogen attenuates homologous upregulation of gonadotropin-releasing hormone receptor mRNA in primary cultured rat pituitary cells.

Authors:  M Cheon; D Park; Y Park; K Kam; S D Park; K Ryu
Journal:  Endocrine       Date:  2000-12       Impact factor: 3.633

2.  Effect of concomitant progesterone administration or the effect of removal of estrogen capsule on changes caused by long-term estrogen treatment in pituitary VIP immunoreactivities.

Authors:  Andrea Heinzlmann; Katalin Köves; György M Nagy
Journal:  Endocrine       Date:  2010-03-30       Impact factor: 3.633

Review 3.  Hirsutism, virilism, polycystic ovarian disease, and the steroid-gonadotropin-feedback system: a career retrospective.

Authors:  Virendra B Mahesh
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-10-25       Impact factor: 4.310

4.  The characteristic change in the distribution of S-100 immunoreactive folliculostellate cells in rat anterior pituitary upon long-term estrogen treatment is prevented by concomitant progesterone treatment.

Authors:  Andrea Heinzlmann; Katalin Köves
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

5.  Pituitary Sex Steroid Receptors: Localization and Function.

Authors:  Lucia Stefaneanu
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

6.  Sexual dimorphism in the effect of concomitant progesterone administration on changes caused by long-term estrogen treatment in pituitary hormone immunoreactivities of rats.

Authors:  Andrea Heinzlmann; Katalin Koves; Magdolna Kovacs; Valer Csernus
Journal:  Med Sci Monit       Date:  2011-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.